US 11,913,036 B2
Engineered acetate kinase variant enzymes
Margie Tabuga Borra-Garske, Palo Alto, CA (US); Oscar Alvizo, Fremont, CA (US); Lillian Jasmine Miller, Saratoga, CA (US); and Aksiniya Lyubenova Petkova, Sunnyvale, CA (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Apr. 1, 2022, as Appl. No. 17/711,451.
Claims priority of provisional application 63/170,017, filed on Apr. 2, 2021.
Prior Publication US 2022/0325256 A1, Oct. 13, 2022
Int. Cl. C12N 9/12 (2006.01)
CPC C12N 9/1217 (2013.01) [C12Y 207/02001 (2013.01)] 17 Claims
 
1. An engineered acetate kinase comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 2 and/or 4, or a functional fragment thereof, wherein the polypeptide sequence of said engineered acetate kinase comprises at least one substitution at position 294, or substitution set comprising a substitution at position 294 and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NOs: 2 and/or 4.